Table 4 9p24.1 Amplified renal cell carcinomas: molecular profiling

From: JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management

Case identifier

Sequencing platform

Tumor mutation burden (mutations/megabase)a

Mutations

Copy number changes

Structural variants

Case 1 (Discovery cohort)

MSK-IMPACT (468 gene panel)

2.6 (Purity: 24%)

PTEN p.X212_splice, FOXO1 p.F14L, TP53 p.G334W

CEBPA/JAK2/PD-L1/PDL-2 Amplified

Case 2 (Discovery cohort)

MSK-IMPACT (410 gene panel)

2.0 (Purity: 33%)

MYOD1 p.R203C, RASA1 p.H1021Y

CDKN2Ap16INK4A/CDKN2Ap14ARF/CDKN2B Loss

PTPRD/JAK2/PD-L1 Amplified

Case 3 (Discovery cohort & Casuscelli et al.)

MSK-IMPACT (341 gene panel)

2.2 (Purity: 38%)

TP53 p.R196X, PTEN p.Y346C

CRKL/JAK2/PD-L1 Amplified

Case 4 (Discovery cohort)

MSK-IMPACT (468 gene panel)

5.3 (Purity: 45%)

TRAF7 p.R641H, ANKRD11 p.R82Q, MST1R p.G231D, PDGFRA p.L686V, PARK2 p.R334C, RAC1 p.N111T

3p Loss, JAK2/PD-L1/PDL-2 Amplified

Case 5 (Discovery cohort)

MSK-IMPACT (410 gene panel)

7.9 (Purity: 27%)

TP53 p.C135Y, AXIN1 p.A552P, DNMT3A p.A84T, NTRK1 p.A612T, NTRK1 p.G643D, VHL p.L169*, PBRM1 splice variant c.2567+1G>C, SPEN splice variant c.1043A>T

JAK2/PD-L1 Amplified

Case 6 (TCGA-BP-4983)

Whole exome sequencing

SETD2 p. P2288Ifs*22, ASXL1 p.E997*, SPEN p.V1129I, TRAF7 p.R524Q, ACAN p.V94M, AMPH p.K112N, CACNA1E p.G310W, CHAD p.A94V, CYLC1 p.L110F, CYP2B6 p.T303I

JAK2/PD-L1/PDL-2 Amplified

Fusions with genes on 9p24.1 (DOCK8-JAK2 & CD274-KANK1) in the setting of 9p24.1 Amplification (including JAK2/PD-L1/PDL-2)

Case 7 (Validation cohort)

None

Case 8 (Validation cohort)

None

Case 9 (Validation cohort)

None

Case 10 (Validation cohort)

None

Case 11 (TCGA-CZ-5468)

Whole exome sequencing

APC p.A1884S, INPP4A p.L202W, MUTYH p.T490Pfs*67, AGO2 p.P484A, AGO2 p.M483I, CDK12 p.L649R, ABCA4 p.R152*, ABCA4 p.Q2104H, BCHE p.W550R, CDH7 p.L605H

3p Loss & JAK2/PD-L1/PDL-2 Amplification

Case 12 (TCGA-B8-4143)

Whole exome sequencing

BAP1 p.Y627*, DICER1 p.E731*, BRAF p.N49I, SMO p.A235T, SOX9 p.D444E, AMPD1 p.K375*, RCBTB2 p.Y299F, CHRM5 p.W271*, GALC p.K628T, GNAT2 p.D103G

JAK2 Amplification

 

Case 13 (Casuscelli et al.)

Targeted gene panel

BARD1 p.L359_P365del, BLM p.R15C, NOTCH3 p.G2081V, NTRK2 p.P204H, KMT2D p.A2620T, SOCS1 p.Q210H

TBX3 Loss, MYC/NBN/SPOP/PD-L1 Amplified

  1. TCGA The Cancer Genome Atlas, MSK-IMPACT Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets.
  2. aAverage TMB for RCCs in the MSK Clinical Sequencing Cohort = 3.0mt/MB. Tumor purity predictions based on FACETS [50]